Business
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n - Treatment with intravenous pelareorep plus azacitidine reduced tumor burden\n \n \n \n \n - Treatment with pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses\n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n ,\n \n Dec. 15, 2021\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) announced preclinical data demonstrating the synergistic anti-leukemic effects of pelareorep combined with the chemotherapeutic agent azacitidine. The data were featured in a poster presentation at the\n \n 2021 American Society of Hematology (ASH) Annual Meeting\n \n , which took place from December 11-14, 2021, in Atlanta,\n \n Georgia\n \n .\n \n \n \n \n \n Preclinical studies featured in the poster evaluated pelareorep in combination with azacitidine in acute myeloid leukemia (AML) cells\n \n in vitro\n \n and in a leukemia xenograft mouse model. Key data and conclusions from the poster include:\n \n \n \n Compared to either treatment alone, treatment with pelareorep plus azacitidine led to a statistically significant reduction (p<0.01) in tumor burden in a leukemia xenograft mouse model\n \n \n Compared to either treatment alone, treatment with pelareorep plus azacitidine led to a statistically significant (p<0.001) synergistic enhancement of anti-leukemic activity against AML cell lines, a benefit that was confirmed in AML patient samples\n \n in vitro\n \n \n \n Th...